Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder

BJU International

Volumn 94, Issue 1, 2004, Pages 18-21

  Konety, Badrinath R ^a,b   Williams, Richard D ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Management; Superficial bladder cancer; Transitional cell carcinoma

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; ETHAMBUTOL; GEMCITABINE; ISONIAZID; MITOMYCIN C; PYRIDOXINE; QUINOLONE DERIVATIVE; RIFAMPICIN; THIOTEPA; VALRUBICIN;

BLADDER CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER RISK; DISEASE ASSOCIATION; DISEASE COURSE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; SHORT SURVEY; URINE CYTOLOGY;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; URINARY BLADDER NEOPLASMS;

EID: 3242751348     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04894.x     Document Type: Short Survey

References (27)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thum M. Cancer Statistics 2003. CA Cancer J Clin 2003; 53: 5-26
2. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1993; 342: 469-71
3. Prat E, Bernues M, Caballin MR, Egozcue J, Gelabert A, Miro R. Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology 2001; 57: 986-92
4. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001; 165: 600-11
5. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003; 169: 1975-82
6. Halling KC, King W, Sokolova IA et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002; 167: 2001-6
7. Lokeshwar VB, Block NL. HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am 2000; 27: 53-61
8. Konety BR, Nguyen TS, Brenes G et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000; 164: 634-9
9. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285: 324-8
10. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162: 74-6
11. Angulo JC, Lopez JI, Grignon DJ, Sanchez-Chapado M. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 1995; 45: 47-53
12. Lopez JI, Angulo JC. The prognostic significance of vascular invasion in stage T1 bladder cancer. Histopathology 1995; 27: 27-33
13. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003; 95: 588-97
14. Solsona E, Iborra I, Ricos JV et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long term followup. J Urol 1999; 161: 1120-3
15. Shahin O, Thalmann GN, Rentsch C et al. A retrospective analysis of 153 patients treated with or without intravesical Bacillus Calmette Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003; 169: 96-100
16. Peyromaure M, Guerin F, Amsellem-Ouazana D et al. Intravesical Bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 2003; 169: 2110-2
17. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999; 161: 1124-7
18. Au JL, Badalament RA, Wientjes MG et al. and the International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C. results of a randomized phase III trial. J Natl Cancer Inst 2001; 93: 597-604
19. Lamm DL, Blumenstein BA, Crissman JD et al. maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000; 163: 1124-9
20. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-70
21. Durek C, Jurczok A, Werner H, Jocham D, Bohle A. Optimal treatment of systemic bacillus Calmette-Guerin infection: investigations in an animal model. J Urol 2002; 168: 826-31
22. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; 163: 761-7
23. O'Donnell MA, Krohn J, Dewolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001; 166: 1300-5
24. Dalbagni G, Russo P, Sheinfeld J et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002; 20: 3193-8
25. Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 2001; 166: 1633-8
26. Joudi FN, Smith BJ, O'Donnell MA, Konety BR. Contemporary management of superficial bladder cancer in the United States - a pattern of care analysis. Urology 2003; 62: 1083-8
27. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001; 166: 1296-9